EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

One versus 2 years of alendronate following denosumab: the CARD extension

Joy N Tsai, Mackenzie Jordan, Hang Lee, Benjamin Z Leder

Osteoporosis International · 2024-12 · 35 (12) · 2225-2230

DOI: 10.1007/s00198-024-07213-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Osteoporosis International, online erschienen am 07.08.2024. Verfasst von Joy N Tsai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA. jntsai@mgh.harvard.edu. Hauptthemen laut MEDLINE: Denosumab, Alendronate, Bone Density Conservation Agents, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabAlendronateBone Density Conservation AgentsOsteoporosis, PostmenopausalBone DensityDrug Administration ScheduleHumansFemaleAgedMiddle AgedOsteoporotic FracturesBone RemodelingLumbar VertebraeBiomarkersFemur Neck

Stichwörter der Autor:innen

AlendronateDenosumabDenosumab cessationOsteoporosis

Substanzen

DenosumabAlendronateBone Density Conservation AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA. jntsai@mgh.harvard.edu.
  • Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
  • Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.

Zitieren

APA

Tsai, J. N., Jordan, M., Lee, H., & Leder, B. Z. (2024). One versus 2 years of alendronate following denosumab: the CARD extension. Osteoporosis International, 35(12), 2225-2230. https://doi.org/10.1007/s00198-024-07213-2

Vancouver

Tsai JN, Jordan M, Lee H, Leder BZ. One versus 2 years of alendronate following denosumab: the CARD extension. Osteoporosis International. 2024;35(12):2225-2230. doi:10.1007/s00198-024-07213-2

BibTeX
@article{Tsai2024,
  author = {Tsai, Joy N and Jordan, Mackenzie and Lee, Hang and Leder, Benjamin Z},
  title = {One versus 2 years of alendronate following denosumab: the CARD extension},
  journal = {Osteoporosis International},
  year = {2024},
  volume = {35},
  number = {12},
  pages = {2225--2230},
  doi = {10.1007/s00198-024-07213-2}
}
Kostenlos starten →